Identify small impurities introduced by oligonucleotide synthesis prior to experimentation.

Researchers use Perturb-CITE-seq to perform powerful multiomic pooled CRISPR screens.

Unravel genomic and proteomic complexity using single cell approaches.

A quantitative immunofluorescence assay combines the best aspects of traditional Western blots and ELISAs.

An integrated guide to maximize RT-qPCR success rates for viral detection assays

Discover how to diagnose and fix problems with pH meter electrode function.

Experience the past, present, and future of CRISPR technology.

Learn how researchers use CRISPR-mediated loss-of-function screens in drug discovery.

Make the best choices for every step of the protein blotting process.

Researchers use long custom oligos to screen viral genome stability with an NGS workflow.

Discover typical routes of mycoplasma contamination and strategies to prevent contamination in the cell culture room.

Researchers develop strategies to prevent and treat diseases with nucleic acid therapies.

DNASTAR announced today the release of Lasergene 17.3, which includes new features and functionality focused on genomic analysis and variant identification supporting COVID-19 research. 

Big discoveries come from miniaturized assays

The CRISPR-Cas system, supported by advances in plate reader technology, has transformed drug discovery processes.

A fully electronic pipette improves results by reducing variance and user fatigue.

The Baker Company, Inc. ("Baker") headquartered in Sanford, Maine U.S.A is pleased to announce the appointment of Diko Strietman to Vice President & Commercial Director, Baker Europe. Mr. Strietman will serve as Baker's top commercial executive representing each of the operating companies and associated brands within the EMEA. In this capacity he will guide strategic growth plans as well as provide oversight and direction over the commercial activities and customer facing personnel within Europe and the UK.

Modern plate readers perform a wide range of applications, making them invaluable for microbiome research.

Explore tissue-specific protocols for growing organoids from primary tissue or stem cells.

Explore an in situ transcriptomic approach for mapping target genes in heterogeneous tumor tissues.